Concepedia

Publication | Open Access

Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway

DOIFull Paper Access

38

Citations

0

References

2018

Year

Zhenghuan Fang, Kyung Hee Jung, Hong Yan, Soo-Jung Kim, Marufa Rumman, Jung Hee Park, Boreum Han, Ji Eun Lee, Yeo Wool Kang, Joo Han Lim,
Cellular Physiology and Biochemistry

Abstract

Melatonin reinforces the anticancer activity of sorafenib by downregulation of PDGFR-β/STAT3 signaling pathway and melatonin receptor (MT)-mediated STAT3. The combination of the two agents might be a potential therapeutic strategy for treating PDAC.